We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Development of Better LNP-Based Genetic Medicines

Development of Better LNP-Based Genetic Medicines content piece image

Lipid nanoparticles (LNPs) are effective non-viral vectors, which are widely used delivery vehicles for genetic medicines. It is therefore important to understand and limit LNP-related impurities to help ensure genetic product integrity and mitigate risks to patient safety and product efficacy. To keep up with global demand, there is also a need to shorten development timelines for gene-based therapeutics and vaccines.

Download this eBook to learn more about:

  • Critical quality attributes of LNPs
  • mRNA and RNA purity
  • Determination of oligonucleotide structures
  • Characterization of lipids and related impurities